Technology evaluation: IMC-1C11, ImClone systems

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 4, 2001, Pages 418-424

  Hunt, S ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; ENDOSTATIN; IMC 1C11; MONOCLONAL ANTIBODY LM 609; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2 MONOCLONAL ANTIBODY; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 0034879569     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ImClone reports preclinical advances on anti-angiogenic lead at American Association for Cancer Research meeting
2. ImClone Systems expands program in cancer-related angiogenesis
3. ImClone systems incorporated reports on anti-angiogenesis data at American Association for Cancer Research Meeting
4. Chimerized anti-KDR IgG from scFv originally isolated from a phage-display library retains specificity for KDR, blocks VEGF binding to the receptor and inhibits VEGF-induced mitogenesis of human umbilical vein endothelial cells
5. Monoclonal antivascular endothelial growth factor (VEGF) receptor (KDR) antibodies which are inhibitors of VEGF binding and antagonists of VEGF-stimulated signalling and growth of human endothelial cells
6. Characterization and quantitation of peptide- MHC complexes produced from hen egg lysozyme using a monoclonal antibody
7. ImClone's collaborators demonstrate inhibition of angiogenesis in a model of AIDS-associated Kaposi's sarcoma
8. ImClone presents preclinical data on its anti-angiogenesis program
9. Effect of anti-VEGF receptor monoclonal antibodies on tumor growth and angiogenesis in SCID mouse/human skin graft model
10. Neutralizing MoAb to VEGF receptor inhibit proliferation and migration of a subset of human leukemias through interaction with VEGFR-2 and VEGFR-1
11. ImClone receives grant for anti-angiogenesis research from National Cancer Institute
12. ImClone systems presents preclinical findings on anti-angiogenesis therapeutic, DC-101, in combination with low-dose chemotherapy at AACR annual meeting
13. ImClone presents data on active immunization against Flk-1 protein to inhibit angiogenesis in a preclinical model
14. Response of human tumor xenografts to the combined use of anti-Flk-1 monoclonal antibody with radiation
15. Vascular endothelial growth factor receptor (VEGFR) antibody therapy, combined with conventional chemotherapy, inhibits the growth of established tumors in mice
16. Dose and frequency modification of conventional chemotherapeutic regimen has anti-angiogenesis effects, and when combined with anti-Flk-1 monoclonal antibody, results in full xenograft regression. No toxicity resistance
17. ImClone Systems presents preclinical data on safety and anti-angiogenic activity of therapeutic antibody IMC-1C11
18. Safety profile in primates and anti-angiogenics activity in murine and canine models of a chimeric antibody directed against the vascular endothelial growth factor receptor 2
19. ImClone Systems commences patient treatment in phase I clinical trial of its anti-angiogenesis agent, IMC-1C11
20. Therapy of metastatic transitional cell carcinoma of the bladder with the anti-vascaular cell growth factor receptor (flk1/KDR) monoclonal antibody DC101 and paclitaxel
21. Angiogenesis and Cancer: From basic mechanisms to Therapeutic applications in an American Association for Cancer Research Special Conference
22. Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-gp75 monoclonal antibody
23. Inhibition of both autocrine and paracrine VEGF/VEGFR-2 angiogenic pathways is essential to induced long-term remission of human leukemias xenotransplanted into NOD-SCID mice
24. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
25. ImClone Systems presents preclinical findings on anti-VEGF receptor therapy in human leukemia model
26. Anti-angiogenesis Therapy revisited: Targeting both paracrine and autocrine neutralizing antibodies to VEGFR-2 is essential to inhibit tumor growth
27. Treatment of human prostate cancer in an orthotopic murine model with anti-vascular endothelial growth factor receptor monoclonal antibody DC101
28. Anti-vascular endothelial factor receptor-2 monoclonal antibody DC-101 inhibits the growth of human renal cell carcinoma xenografts in nude mice